Colossal Biosciences Eyes $20B–$30B Valuation in New Funding Round

Colossal Biosciences, the pioneering de-extinction company, is reportedly in discussions to secure new funding that could value the firm at $20 billion to $30 billion. According to sources familiar with the matter, this would represent a significant leap from its prior valuation, reflecting growing investor confidence in its ambitious mission to revive extinct species such as the woolly mammoth and the thylacine. The company has been at the forefront of genetic engineering and synthetic biology, leveraging advanced CRISPR technology and computational biology to tackle conservation challenges. If successful, this funding round would position Colossal as one of the most valuable private biotech companies globally, underscoring the market's appetite for transformative science with real-world impact.